| 1 |
Martin-Loeches I, Singer M, Leone M. Sepsis: key insights, future directions, and immediate goals. A review and expert opinion [J]. Intensive Care Med, 2024, 50 (12): 2043-2049.
|
| 2 |
Xiao Y, Yuan Y, Hu D, et al. Exosome-derived microRNA: potential target for diagnosis and treatment of sepsis[J]. J Immunol Res, 2024, 2024: 4481452.
|
| 3 |
Hornisch M, Piazza I. Regulation of gene expression through protein-metabolite interactions [J]. NPJ Metab Health Dis, 2025, 3 (1): 7.
|
| 4 |
Barrett A, Shingare MR, Rechtsteiner A, et al. HDAC activity is dispensable for repression of cell-cycle genes by DREAM and E2F:RB complexes [J]. Nat Commun, 2024, 15 (1): 4450.
|
| 5 |
Wu Y, He Y, Liu C, et al. Histone deacetylase inhibitor (SAHA) reduces mortality in an endotoxemia mouse model by suppressing glycolysis [J]. Int J Mol Sci, 2023, 24 (15): 12448.
|
| 6 |
Hosseini MS, Sanaat Z, Akbarzadeh MA, et al. Histone deacetylase inhibitors for leukemia treatment: current status and future directions [J]. Eur J Med Res, 2024, 29 (1): 514.
|
| 7 |
Baretti M, Danilova L, Durham JN, et al. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial[J]. Nat Commun, 2024, 15 (1): 9801.
|
| 8 |
Zhu M, Tang W, Tang X, et al. Cantharidin overcomes IL-2Ralpha signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species [J]. J Immunother Cancer, 2024, 12 (7): e009099.
|
| 9 |
Watson N, Kuppuswamy S, Ledford WL, et al. The role of HDAC3 in inflammation: mechanisms and therapeutic implications [J]. Front Immunol, 2024, 15: 1419685.
|
| 10 |
Gu Z, Lin S, Yu J, et al. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment [J]. Eur J Med Chem, 2024, 275: 116571.
|
| 11 |
Bhat MF, Srdanovic S, Sundberg LR, et al. Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections [J]. Drug Discov Today, 2024, 29 (11): 104193.
|
| 12 |
Sharma D, Panchaksaram M, Muniyan R. Advancements in understanding the role and mechanism of sirtuin family (SIRT1-7) in breast cancer management [J]. Biochem Pharmacol, 2025, 232: 116743.
|
| 13 |
Cheng Y, Zhao A, Li Y, et al. Roles of SIRT3 in cardiovascular and neurodegenerative diseases [J]. Ageing Res Rev, 2025, 104: 102654.
|
| 14 |
Bai X, Liu Y, Liu J, et al. ADSCs-derived exosomes suppress macrophage ferroptosis via the SIRT1/NRF2 signaling axis to alleviate acute lung injury in sepsis [J]. Int Immunopharmacol, 2025, 146: 113914.
|
| 15 |
Khatun S, Prasad Bhagat R, Dutta R, et al. Unraveling HDAC11: epigenetic orchestra in different diseases and structural insights for inhibitor design [J]. Biochem Pharmacol, 2024, 225: 116312.
|
| 16 |
He R, He Z, Zhang T, et al. HDAC3 in action: expanding roles in inflammation and inflammatory diseases[J]. Cell Prolif, 2025, 58 (1): e13731.
|
| 17 |
Sun S, Xu Z, He L, et al. Metabolic regulation of cytoskeleton functions by HDAC6-catalyzed alpha-tubulin lactylation [J]. Nat Commun, 2024, 15 (1): 8377.
|
| 18 |
Lv Z, Ji T, Liu J, et al. Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review [J]. Eur J Med Chem, 2025, 283: 117185.
|
| 19 |
Yao M, Yan W, Wang Y, et al. IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response[J]. Exp Hematol Oncol, 2025, 14 (1): 15.
|
| 20 |
Yuan Y, Xiao Y, Zhao J, et al. Exosomes as novel biomarkers in sepsis and sepsis related organ failure[J]. J Transl Med, 2024, 22 (1): 1078.
|
| 21 |
Zhang SY, Zhang LY, Wen R, et al. Histone deacetylases and their inhibitors in inflammatory diseases[J]. Biomed Pharmacother, 2024, 179: 117295.
|
| 22 |
Finkelstein RA, Li Y, Liu B, et al. Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock [J]. J Surg Res, 2010, 163 (1): 146-154.
|
| 23 |
沈沛，何国丽，徐娜娜，等.脓毒症相关性急性肺损伤信号通路的研究进展[J/OL].中华危重症医学杂志（电子版），2024，17（4）：326-330.
|
| 24 |
Li Y, Ai S, Li Y, et al. The role of natural products targeting macrophage polarization in sepsis-induced lung injury[J]. Chin Med, 2025, 20 (1): 19.
|
| 25 |
Xu Y, Liu J, Wang J, et al. USP25 stabilizes STAT6 to promote IL-4-induced macrophage M2 polarization and fibrosis[J]. Int J Biol Sci, 2025, 21 (2): 475-489.
|
| 26 |
杨宏富，李平娜，崔秋敏，等.脓毒症患者淋巴细胞亚群分析及其对预后的影响[J].中华危重病急救医学，2023，35（7）：702-706.
|
| 27 |
Pu J, Liu T, Wang X, et al. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives [J]. Exp Hematol Oncol, 2024, 13 (1): 45.
|
| 28 |
Wu D, Shi Y, Zhang H, et al. Epigenetic mechanisms of immune remodeling in sepsis: targeting histone modification [J]. Cell Death Dis, 2023, 14 (2): 112.
|
| 29 |
Zhou Y, Luo Q, Zeng F, et al. Trichostatin A promotes cytotoxicity of cisplatin, as evidenced by enhanced apoptosis/cell death markers [J]. Molecules, 2024, 29 (11): 2623.
|
| 30 |
吴丰盛，刘瑜，刘海英，等.曲古霉素A对脂多糖诱导的人微血管内皮细胞损伤和凋亡的影响[J].中国小儿急救医学，2023，30（3）：203-207.
|
| 31 |
Chen F, Li X, Aquadro E, et al. Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension[J]. Free Radic Biol Med, 2016, 99: 167-178.
|
| 32 |
Yang L, Wu C, Cui Y, et al. Knockdown of histone deacetylase 9 attenuates sepsis-induced myocardial injury and inflammatory response[J]. Exp Anim, 2023, 72 (3): 356-366.
|
| 33 |
Kuai Q, Wang C, Wang Y, et al. Energy metabolism regulated by HDAC inhibitor attenuates cardiac injury in hemorrhagic rat model [J]. Sci Rep, 2016, 6 (1): 38219.
|
| 34 |
陈瑞，王丽，徐海乐，等.早期监测白细胞介素35联合肝素结合蛋白对脓毒症相关急性肾损伤的预测价值[J/OL].中华危重症医学杂志（电子版），2025，18（2）：122-127.
|
| 35 |
Zhang H, Zhang W, Jiao F, et al. The nephroprotective effect of MS-275 on lipopolysaccharide (LPS)-induced acute kidney injury by inhibiting reactive oxygen species (ROS)-oxidative stress and endoplasmic reticulum stress[J]. Med Sci Monit, 2018, 24: 2620-2630.
|
| 36 |
Huang HM, Zhou XR, Liu YJ, et al. Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation [J]. Mol Med Rep, 2021, 23 (5): 305.
|
| 37 |
Ding D, Chen LL, Zhai YZ, et al. Trichostatin A inhibits the activation of Hepatic stellate cells by increasing C/EBP-α acetylation in vivo and in vitro[J]. Sci Rep, 2018, 8 (1): 4395.
|
| 38 |
Zhao L, Tang H, Cheng Z. Pharmacotherapy of liver fibrosis and hepatitis: recent advances [J]. Pharmaceuticals (Basel), 2024, 17 (12): 1724.
|
| 39 |
Lin X, Han H, Wang N, et al. The gut microbial regulation of epigenetic modification from a metabolic perspective[J]. Int J Mol Sci, 2024, 25 (13): 7175.
|
| 40 |
Zhao T, Li Y, Liu B, et al. Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsis [J]. Surgery, 2014, 156 (2): 214-220.
|
| 41 |
Theodoropoulou MA, Mantzourani C, Kokotos G. Histone deacetylase (HDAC) inhibitors as a novel therapeutic option against fibrotic and inflammatory diseases[J]. Biomolecules, 2024, 14 (12): 1605.
|
| 42 |
Niu K, Yang L, Song W, et al. A comparative analysis to determine the optimum histone deacetylase inhibitors and administration route for improving survival and organ injury in rats after hemorrhagic shock[J]. Shock, 2023, 60 (1): 75-83.
|
| 43 |
高芮，马晓媛，梁华平，等.脓毒症治疗药物的研究进展[J/OL].中华危重症医学杂志（电子版），2024，17（2）：155-163.
|
| 44 |
Ibrahim ML, Zheng H, Barlow ML, et al. Histone deacetylase inhibitors directly modulate T cell gene expression and signaling and promote development of effector-exhausted T cells in murine tumors [J]. J Immunol, 2024, 212 (4): 737-747.
|
| 45 |
Pei F, Gu B, Miao SM, et al. Clinical practice of sepsis-induced immunosuppression: current immunotherapy and future options [J]. Chin J Traumatol, 2024, 27 (2): 63-70.
|
| 46 |
Joerger M, Koster KL, Janik T, et al. Combination therapy with immune checkpoint inhibitors and histone deacetylase inhibitors or alkylating agents [J]. Cancer Manag Res, 2024, 16: 855-869.
|
| 47 |
Dai W, Qiao X, Fang Y, et al. Epigenetics-targeted drugs: current paradigms and future challenges [J]. Signal Transduct Target Ther, 2024, 9 (1): 332.
|